117 HR 7529 IH: Plain Prescription Prices Act U.S. House of Representatives 2022-04-14 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I117th CONGRESS2d SessionH. R. 7529IN THE HOUSE OF REPRESENTATIVESApril 14, 2022Ms. Williams of Georgia (for herself, Mr. Bacon, Ms. Craig, and Mr. Steil) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concernedA BILLTo require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information.

1.

Short title

This Act may be cited as the Plain Prescription Prices Act.

2.

Regulating advertisements for prescription drug and biological product prices

(a)

In general

Not later than one year after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Administrator of the Centers for Medicare & Medicaid Services (referred to in this section as the Administrator), shall promulgate regulations requiring each direct-to-consumer advertisement on television (including broadcast, cable, streaming, and satellite television) for a prescription drug or biological product for which payment is available under title XVIII or XIX of the Social Security Act to include a textual statement, which shall be truthful and not misleading, indicating the list price, as determined on the first day of the quarter during which the advertisement is being aired or otherwise broadcast, for a typical 30-day regimen or typical course of treatment (whichever is most appropriate).(b)

Determinations

In promulgating regulations under subsection (a), the Administrator shall determine—(1)whether such regulations should apply with respect to additional forms of advertising;(2)the manner and format of textual statements described in such subsection;(3)appropriate enforcement mechanisms; and(4)whether such textual statements should include any other price information, as appropriate.